VACCINATION AS PRIMARY CONTACT WITH INFLUENZA A AND B VIRUSES

PEDIATRICS ◽  
1949 ◽  
Vol 3 (2) ◽  
pp. 208-213
Author(s):  
RAE V. NICHOLAS ◽  
WERNER HENLE
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Influenza A ◽  
Infectious Agents ◽  
Older Individuals ◽  
Protective Measures ◽  
Primary Contact ◽  
Small Doses ◽  
Antibody Levels ◽  
Booster Effect

A single dose of 0.5 ml. of commercially available influenzal virus vaccine injected into children from seven weeks to three years of age produced antibodies in about 70%. Resulting antibody levels in the children, most of whom were born after the last widespread epidemics of influenza A and B, were distinctly lower than those observed in older individuals who, in all likelihood, had experienced previous contacts with influenzal antigens. Two injections at a week's interval failed to result in a better antibody response in these children in agreement with the experience gained in adults. Increase in the dose of vaccine appears unwarranted now, since the incidence of febrile reactions—all of short duration—exceeded 40%. This inferior antibody response may be the result of several factors: (a) the smaller dose of vaccine which can be safely administered to such children; (b) the possible inferior immune response of the younger individual; and (c) the absence of a basic immunity to the antigens present in most older individuals as a result of previous contacts with influenzal viruses. Although it is impossible to decide among these factors, the booster effect of restimulation with small doses of antigen is a well known phenomenon in protective measures against other infectious agents. It is felt that such a mechanism may well be the explanation for the discrepancies between young children and older individuals in their response to vaccination against influenza.

scholarly journals Antibody response after COVID-19 mRNA vaccination in relation to age, sex, and side effects

2021 ◽  
Author(s):  
Paul Naaber ◽  
Virge Jürjenson ◽  
Ainika Adamson ◽  
Epp Sepp ◽  
Liina Tserel ◽  
...  
Keyword(s):  
Immune Response ◽  
Side Effects ◽  
Immune Responses ◽  
Antibody Response ◽  
Older Individuals ◽  
High Efficacy ◽  
Vaccine Response ◽  
Antibody Levels ◽  
The Impact ◽  
Older Males

AbstractBackgroundThe mRNA vaccines for SARS-CoV2 have proven highly effective and are currently used to vaccinate all age groups against COVID-19. Despite their high efficacy in clinical trials, there is limited data on the impact of age, sex, and side effects on vaccine-induced immune responses.MethodsWe here studied the development of SARS-CoV-2 Spike protein RBD domain antibodies after two doses of the Pfizer-BioNTech Comirnaty mRNA vaccine in 118 healthy volunteers and correlated their immune response with age, sex, and side effects reported after the vaccinations.FindingsOur findings show a robust immune response to the Spike protein’s RBD region after the first and the second vaccination dose. However, we also saw a decline of antibody levels at 6 weeks versus 1 week after the second dose, suggesting a waning of the immune response over time. Regardless of this, the antibody levels at 6 weeks after the second dose remained significantly higher than before the vaccination, after the first dose, or in COVID-19 convalescent individuals. We found a decreased vaccination efficacy but fewer adverse events in older individuals, and that mRNA vaccination is less efficient in older males whereas the detrimental impact of age on vaccination outcome is abolished in females at 6 weeks after the second dose.InterpretationThe Pfizer-BioNTech Comirnaty mRNA vaccine induces a strong immune response after two doses of vaccination but older individuals develop fewer side effects and decreased antibody levels at 6 weeks. The waning of anti-viral antibodies in particular in older male individuals suggests that both age and male sex act as risk factors in the immune response to the SARS-CoV-2 mRNA vaccine.FundingThe study was supported by the Centre of Excellence in Translational Genomics (EXCEGEN), and the Estonian Research Council grant PRG377 and SYNLAB Estonia.Research in contextEvidence before this studyThe first studies addressing the immune responses in older individuals after the single-dose administration of the SARS-CoV-2 mRNA vaccines have been published. We searched PubMed and medRxiv for publications on the immune response of SARS-CoV-2-mRNA vaccines, published in English, using the search terms “SARS-CoV-2”, “COVID-19”, “vaccine response”, “mRNA vaccine”, up to April 15th, 2021. To date, most mRNA vaccine response studies have not been peer-reviewed, and data on the role of age, sex and side effects on SARS-CoV-2-mRNA vaccines in real vaccination situations is limited. Some studies have found a weaker immune response in older individuals after the first dose and these have been measured at a relatively short period (within 1-2 weeks) after the first dose but little longer-term evidence exists on the postvaccination antibody persistence. Even less information is available on sex differences or correlations with mRNA vaccine side effects.Added value of this studyIn this study, we assessed the antibody response up to 6 weeks after the second dose of Pfizer-BioNTech Comirnaty mRNA vaccine in 118 individuals. Our findings show a strong initial immune response after the first dose and an even higher Spike RBD antibody levels at 1 week after the second dose, but these significantly declined at 6 weeks after the second dose. We also found a weaker immune response and faster waning of antibodies in older vaccinated individuals, which correlated with fewer side effects at the time of vaccinations. Furthermore, although overall female and male vaccinees responded similarly, we found that age-related waning of the vaccine-related antibodies was stronger amongst older males whereas in females the impact of age was lost at 6 weeks after the second dose.Implications of all the available evidenceNew mRNA vaccines are now applied worldwide as they have shown high efficacy in clinical trials. Our results show that two doses of Pfizer-BioNTech Comirnaty mRNA vaccine induce a strong antibody response to Spike RBD region but these high levels decline 1.5 months after the second dose in most of the vaccinated individuals. Nevertheless, even at 6 weeks after the second dose, they stay significantly higher than at prevaccination, after the first dose of vaccine, or in Covid-19 postinfection. These findings also implicate that fewer adverse effects may indicate lower antibody response after the vaccination and point to the need for more individualized vaccination protocols, in particular among older people.

scholarly journals Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0247797
Author(s):  
Renee L. Higgins ◽  
Stephen A. Rawlings ◽  
Jamie Case ◽  
Florence Y. Lee ◽  
Clarence W. Chan ◽  
...  
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Vaccine Development ◽  
Treatment Strategies ◽  
Lateral Flow ◽  
Patient Specific ◽  
The Novel ◽  
Successful Vaccine ◽  
Novel Coronavirus ◽  
Antibody Levels

Since the initial identification of the novel coronavirus SARS-CoV-2 in December of 2019, researchers have raced to understand its pathogenesis and begun devising vaccine and treatment strategies. An accurate understanding of the body’s temporal immune response against SARS-CoV-2 is paramount to successful vaccine development and disease progression monitoring. To provide insight into the antibody response against SARS-CoV-2, plasma samples from 181 PCR-confirmed COVID-19 patients collected at various timepoints post-symptom onset (PSO) were tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies via lateral flow. Additionally, 21 donors were tracked over time to elucidate patient-specific immune responses. We found sustained levels of anti-SARS-CoV-2 antibodies past 130 days PSO, with 99% positivity observed at 31–60 days PSO. By 61–90 days PSO, the percentage of IgM-/IgG+ results were nearly equal to that of IgM+/IgG+ results, demonstrating a shift in the immune response with a decrease in IgM antibody levels. Results from this study not only provide evidence that the antibody response to COVID-19 can persist for over 4 months, but also demonstrates the ability of Easy Check™ to monitor seroconversion and antibody response of patients. Easy Check was sufficiently sensitive to detect antibodies in patient samples as early as 1–4 days PSO with 86% positivity observed at 5–7 days PSO. Further studies are required to determine the longevity and efficacy of anti-SARS-CoV-2 antibodies, and whether they are protective against re-infection.

THE EFFECT OF AN OESTROGENIC STEROID ON THE SECONDARY IMMUNE RESPONSE UNDER DIFFERENT HORMONAL ENVIRONMENTS

1973 ◽  
Vol 72 (3) ◽  
pp. 582-586 ◽  
Author(s):  
Yasmin M. Thanavala ◽  
Shanta S. Rao ◽  
A. N. Thakur
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Parabolic Type ◽  
Secondary Antibody ◽  
Secondary Immune Response ◽  
Adrenal Hormones ◽  
Enhancing Effect ◽  
High Doses ◽  
Antibody Levels ◽  
Tetanus Antibodies

ABSTRACT The effect of mestranol was studied on the secondary antibody response in mice under different hormonal environments. The results revealed that in the intact and ovariectomized animals treated with the oestrogen, the antibody response was of the parabolic type. In adrenalectomized mice, the administration of the steroid resulted in appreciably elevated levels of anti-tetanus antibodies. The response obtained was similar in animals receiving both the low and high doses of the oestrogen. Removal of both the ovaries and the adrenals resulted in marked increases in the antibody levels. Thus mestranol exerts an enhancing effect on the secondary antibody response in mice. This enhancement is, however, modified and regulated by the endogenous ovarian and adrenal hormones.

scholarly journals ANTIBODY RESPONSE OF HUMAN BEINGS FOLLOWING VACCINATION WITH INFLUENZA VIRUSES

1942 ◽  
Vol 75 (5) ◽  
pp. 495-511 ◽  
Author(s):  
G. K. Hirst ◽  
E. R. Rickard ◽  
Loring Whitman ◽  
F. L. Horsfall
Keyword(s):  
Influenza Virus ◽  
Antibody Response ◽  
Influenza A ◽  
Geometric Mean ◽  
Allantoic Fluid ◽  
Influenza Viruses ◽  
Human Beings ◽  
Significant Difference ◽  
Antibody Levels

Eleven different preparations of influenza virus were used to vaccinate large groups of human beings. The antibody response to these vaccines was measured by means of the in vitro agglutination inhibition test, and the geometric mean titers of sera taken 2 weeks after vaccination were compared. From these comparisons the following conclusions were drawn: 1. There was a wide individual variation in the antibody response of human beings to the same preparation of influenza virus administrated subcutaneously. The amount of antibody produced by a group with a low prevaccination antibody level was very nearly the same as the amount produced by groups that had higher initial levels. 2. The use of the X strain of distemper virus in the preparation of an influenza vaccine did not enhance the antigenicity of the influenza virus present. 3. Within certain limits the mean antibody response of human beings increased as the amount of virus injected was increased. When large amounts of influenza A virus were given, the antibody response was of the same order of magnitude as that which occurred following actual infection by this virus. 4. When the vaccine was prepared from allantoic fluid, there was no significant difference in the antibody response of human beings given active virus, formalin-inactivated virus, heat-inactivated virus, or virus inactivated by the drying process. 5. Ground infected chick embryos, when diluted with infected allantoic fluid, gave a greater antibody response than allantoic fluid alone (when the virus remained active). The antigenicity of such a preparation was diminished when the virus was inactivated by formalin. 6. Antibody levels 6 and 9 weeks after vaccination showed a marked drop from the 2-week postvaccination levels. In a small group the antibody levels at 5 months were still further reduced. Those individuals who possessed the higher titers tended to lose their antibodies faster than did those at a lower level.

scholarly journals STUDIES IN HUMAN IMMUNIZATION AGAINST INFLUENZA

1944 ◽  
Vol 80 (4) ◽  
pp. 265-273 ◽  
Author(s):  
G. K. Hirst ◽  
E. R. Rickard ◽  
W. F. Friedewald
Keyword(s):  
Influenza Virus ◽  
Antibody Response ◽  
Attack Rate ◽  
Influenza A ◽  
Allantoic Fluid ◽  
Great Majority ◽  
High Order ◽  
Human Beings ◽  
Antibody Levels ◽  
A Current

The administration to human beings of formalin-killed influenza virus, concentrated from allantoic fluid, resulted in a high order of antibody response within 2 weeks after injection. Even after 1 year the great majority of individuals vaccinated had antibody levels considerably above their prevaccination titer for the PR8, Lee, and a current 1943 strain. An investigation of the occurrence of epidemic influenza A in seven widely separated populations, 1 year after vaccination of part of these groups, showed that the attack rate among vaccinated persons was consistently lower than that of control individuals. The average reduction in attack rate was of the order of 35 per cent.

scholarly journals Effects of Age, Sex, Serostatus and Underlying Comorbidities on Humoral Response Post-SARS-CoV-2 Pfizer-BioNTech Vaccination: A Systematic Review

2021 ◽  
Author(s):  
Kin Israel Notarte ◽  
Abbygail Therese Ver ◽  
Jacqueline Veronica Velasco ◽  
Adriel Pastrana ◽  
Jesus Alfonso Catahay ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Response ◽  
Older Individuals ◽  
Response Mechanism ◽  
Humoral Immune ◽  
Different Populations ◽  
Male Sex ◽  
Mrna Technology ◽  
Antibody Levels ◽  
Response Post

With the advent of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, several vaccines have been developed to mitigate its spread and prevent adverse consequences of the Coronavirus Disease 2019 (COVID-19). The mRNA technology is an unprecedented vaccine, usually given in two doses to prevent SARS-CoV-2 infections. Despite effectiveness and safety, inter-individual immune response heterogeneity has been observed in recipients of mRNA-based vaccines. As a novel disease, the specific immune response mechanism responsible for warding off COVID-19 remains unclear at this point. However, significant evidence suggests that humoral response plays a crucial role in affording immunoprotection and preventing debilitating sequelae from COVID-19. As such this paper focused on the possible effects of age, sex, serostatus, and comorbidities on humoral response (i.e., total antibodies, IgG and/or IgA) of different populations post-mRNA-based Pfizer-BioNTech vaccination. A systematic search of literature was performed through PubMed, Cochrane CENTRAL, and Google Scholar. Studies were included if they reported humoral response to COVID-19 mRNA vaccines. A total of 32 studies was identified and reviewed, and the percent difference of means of reported antibody levels were calculated for comparison. Findings revealed that older individuals, the male sex, seronegativity, and those with more comorbidities mounted less humoral immune response. Given these findings, several recommendations were proposed regarding the current vaccination practices. These include giving additional doses of vaccination for immunocompromised and elderly populations. Another recommendation is conducting clinical trials in giving a combined scheme of mRNA vaccines, protein vaccines, and vector-based vaccines.

scholarly journals Pausing methotrexate improves immunogenicity of COVID-19 vaccination in patients with rheumatic diseases

2021 ◽  
Author(s):  
Amanthi Nadira Arumahandi de Silva ◽  
Leonie Maria Frommert ◽  
Fredrik N Albach ◽  
Jens Klotsche ◽  
Veronika Scholz ◽  
...  
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Rheumatic Diseases ◽  
Control Group ◽  
Dependent Manner ◽  
Humoral Immune ◽  
Time Period ◽  
Age Dependent ◽  
Antibody Levels ◽  
The Impact

Objective: To study the effect of methotrexate (MTX) and its discontinuation on the humoral immune response after COVID-19 vaccination in patients with autoimmune rheumatic diseases (AIRD). Methods: Neutralising SARS-CoV-2 antibodies were measured after second vaccination in 64 rheumatic patients on methotrexate therapy, 31 of whom temporarily paused medication without a fixed regimen. The control group consisted of 21 AIRD patients without immunosuppressive medication. Results: MTX patients showed a significantly lower median antibody response compared to AIRD patients without immunosuppressive therapy (p< 0.001). Young age (<60 years) and MTX-hold after vaccination were found to be the main factors influencing antibody response after vaccination, while BMI or MTX dose demonstrated no effect. For patients taking MTX, age correlated negatively with immune response (r=-0.49; p<0.001) and all patients with antibody levels (14 %) below the cut-off were older than 60 years. Patients who held MTX during at least one vaccination showed significantly higher median neutralising antibody levels after second vaccination, compared to patients who continued MTX therapy during both vaccinations (68.82 %, 92.73 %, p=<0.001). This effect was particularly pronounced in patients older than 60 years (p=0.0016). The impact of the time period after vaccination was greater than of the time before vaccination with the critical cut-off being 10 days. Conclusion: MTX reduces the immunogenicity of SARS-CoV-2 vaccination in an age-dependent manner. Our data further suggest that holding MTX for at least 10 days after vaccination significantly improves the antibody response in patients over 60 years of age.

scholarly journals Modulation of parasitemia and antibody responce to Trypanosoma cruzy by cyclophosphamide in Calomys callosus (Rodentia, Cricetidae)

1992 ◽  
Vol 34 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Monamaris Marques Borges ◽  
Paulo Roberto Curi ◽  
Judith Kardos Kloetzel
Keyword(s):  
Immune Response ◽  
Body Weight ◽  
Antibody Response ◽  
Passive Transfer ◽  
Additional Dose ◽  
Wild Rodent ◽  
Susceptibility To Infection ◽  
Calomys Callosus ◽  
Antibody Levels ◽  
Cruzi Infection

Calomys callosus a wild rodent, previously described as harboring Trypanosoma cruzi, has a low susceptibility to infection by this protozoan. Experiments were designed to evaluate the contribution of the immune response to the resistance to T. cruzi infection exhibited by C. calossus. Animals were submitted to injections of high (200 mg/kg body weight) and low (20 mg/kg body weight) doses of cyclophosphamide on days -1 or -1 and +5, and inoculated with 4 x 10³ T. cruzi on day O. Parasitemia, mortality and antibody response as measured by direct agglutination of trypomastigotes were observed. Two hundred mg doses of cyclophosphamide resulted in higher parasitemia and mortality as well as in suppression of the antibody response. A single dose of 20 mg enhanced antibody levels on the 20th day after infection, while an additional dose did not further increase antibody production. Parasitemia levels were not depressed, but rather increased in both these groups as compared to untreated controls. Passive transfer of hyperimmune C. callosus anti-T. cruzi serum to cyclophosphamide immunosuppressed animals resulted in lower parasitemia and mortality rates. These results indicate that the immune response plays an important role in the resistance of C. callossus to T. cruzi.

Antibody Response to Influenza A/New Jersey and A/Victoria Virus Vaccines in 1976 and Subsequent Antibody Levels after Influenza A Epidemics, 1977-1979

1980 ◽  
Vol 142 (2) ◽  
pp. 139-144 ◽  
Author(s):  
H. M. Foy ◽  
M. K. Cooney ◽  
J. Taylor ◽  
I. Allan ◽  
T.- Y. Chuang ◽  
...  
Keyword(s):  
New Jersey ◽  
Antibody Response ◽  
Influenza A ◽  
Antibody Levels

scholarly journals Antibody response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease – results of a single-center cohort study in a tertiary hospital in Germany

2021 ◽  
Author(s):  
Johanna Maria Classen ◽  
Anna Muzalyova ◽  
Sandra Nagl ◽  
Carola Fleischmann ◽  
Alanna Ebigbo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Immune Response ◽  
Antibody Response ◽  
Bowel Disease ◽  
Positive Impact ◽  
Immunomodulatory Therapy ◽  
Control Group ◽  
Single Center ◽  
Inflammatory Bowel ◽  
Antibody Levels

COVID-19 was first described in 2019, with significant impact on everyday life since then. In 2020, the first vaccine against COVID-19 was approved. Little is known about immune response to vaccination in patients with inflammatory bowel disease (IBD). Aim of our study was to investigate antibody response to SARS-CoV-2 vaccination in IBD patients receiving immunomodulators/biologics compared to healthy controls. This was a single-center retrospective study. 72 patients with IBD were included. Data from 72 healthy employees were used as control group matched by propensity score. Blood samples were analyzed for antibody response. 65 (90.3%) patients of the IBD group received immunomodulatory therapy. Mean antibody level for IBD patients was 1257.1 U/ml (SD 1109.626) in males and 1500.1 U/ml (SD 1142.760) in females (reduced antibody response IBD group 1383.76 U/ml SD 1125.617; control group 1885.65 U/ml SD 727.572, p < 0.05)). There was no vaccination failure in IBD group. After first vaccination, side effects were reported more often in IBD patients (total symptoms IBD group 58.3 %, control group 34.5 %, p < 0.007) with the opposite after the second vaccination (total symptoms IBD group 55.4 %, control group 76 %, p = 0.077)). There was a trend to reduced immune response in elderly. Disease duration and immunomodulatory therapy had no impact on immune response. Longer time to last medication given and time passed to vaccination in IBD group seem to have a positive impact on antibody levels. High antibody response to vaccination in all patients with IBD was seen. Vaccination was well tolerated. Concomitant immunomodulatory therapy had no impact on seroconversion. Antibody levels in the IBD group were lower compared to control group.

Sign in / Sign up

Export Citation Format

Share Document